Viventia Biotech Inc.
Etobicoke, ON
Company Overview
Viventia Biotech Inc. is a Canadian biopharmaceutical company developing Armed Antibodies, powerful and precise anti-cancer drugs designed to overcome various forms of cancer. Viventias lead product is Proxinium, which combines a cytotoxic protein payload significantly more powerful than traditional chemotherapies with the highly precise tumour-targeting characteristics of a monoclonal antibody. Proxinium is in clinical development for the treatment of head and neck cancer and bladder cancer, and is expected to enter advanced clinical trials in 2006.
Company Information
Physical Address
501-10 Four Seasons Place
Etobicoke, ON M9B 6H7
CA
Mailing Address
501-10 Four Seasons Place
Etobicoke, ON M9B 6H7
CA
Additional Details
Legal Name: Viventia Biotech Inc.
Number of Employees: 50
CA
Fully Human Monoclonal Antibodies
Contacts
Nick Glover
Title: Chief Executive Officer
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Domenic Loparco
Title: Corporate Affairs
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Michael Byrne
Title: Chief Financial Officer
Area of Responsibility: Finance/Accounting
Phone: Show phone
Fax: Show fax
Email: Show email
Services
- Biotechnology
Products
-
Molecular Biology And Genetic Engineering
Development of new strategies utilizing molecular and cell biology techniques to produce novel cellular systems for high level expression and production of engineered proteins as a practical way of manufacturing therapeutic proteins on a commercially viable scale
- Pharmaceuticals And Biologicals
Additional Information
541710